HEPARIN AND HEPARAN SULPHATE OLIGOSACCHARIDES

Abstract

Isolated heparin or heparan sulphate oligosaccharide fragments having a chain length of at least 10 saccharides and no more than 50 saccharides, which are capable of binding BMP2, are disclosed. Also disclosed is the use of the same heparin or heparan sulphate oligosaccharide fragments in kits and pharmaceutical compositions, and the use of the same heparan sulphate oligosaccharide fragments in the repair and/or regeneration of connective tissue and bones, and the treatment of wounds.

Claims

1-51. (canceled)

52. A biomaterial that is coated and/or impregnated with an isolated heparin or heparan sulphate oligosaccharide, wherein the isolated heparin or heparan sulphate oligosaccharide has a chain length of at least 12 saccharides and no more than 50 saccharides and is capable of binding BMP2.

53. The biomaterial of claim 52, wherein the biomaterial comprises a scaffold or matrix structure.

54. The biomaterial of claim 52, wherein the biomaterial comprises hydrogel, fibrin, collagen, ceramic, metal, agarose, alginate, chitosan, polycaprolactone, poly(DL-lactide-co-caprolactone), poly(L-lactide-co-caprolactone-co-glycolide), polyglycolide, polylactide, polyhydroxyalcanoates, cellulose acetate; cellulose butyrate, alginate, polysulphone, polyurethane, polyacrylonitrile, sulphonated polysulphone, polyamide, polyacrylonitrile, polymethylmethacrylate, hydroxyapatite, hyaluronic acid, an autograft, or an allograft biomaterial.

55. The biomaterial of claim 52, wherein the isolated heparin or heparan sulphate oligosaccharide has a chain length of about 12 saccharides.

56. The biomaterial of claim 52, wherein the isolated heparin or heparan sulphate is N-sulphated, 6-O sulphated, and/or 2-O de-sulphated.

57. The biomaterial of claim 52, wherein the isolated heparin or heparan sulphate is a fragment of HS3.

58. The biomaterial of claim 52, wherein the isolated heparin or heparan sulphate oligosaccharide has a chain length of 14 to 50 saccharides, 16 to 50 saccharides, 18 to 50 saccharides, 20 to 50 saccharides, 22 to 50 saccharides, 24 to 50 saccharides, 26 to 50 saccharides, 28 to 50 saccharides, 30 to 50 saccharides, 32 to 50 saccharides, 34 to 50 saccharides, 36 to 50 saccharides, 38 to 50 saccharides, 40 to 50 saccharides, 42 to 50 saccharides, 44 to 50 saccharides, 46 to 50 saccharides, or 48 to 50 saccharides.

59. The biomaterial of claim 52, wherein the isolated heparin or heparan sulphate oligosaccharide has a chain length of 12 to 36 saccharides, 14 to 36 saccharides, 16 to 36 saccharides, 18 to 36 saccharides, 20 to 36 saccharides, 22 to 36 saccharides, 24 to 36 saccharides, 26 to 36 saccharides, 28 to 36 saccharides, 30 to 36 saccharides, 32 to 36 saccharides, or 34 to 36 saccharides.

60. The biomaterial of claim 52, wherein the isolated heparin or heparan sulphate oligosaccharide has a chain length of 36 to 50 saccharides, optionally one of 38 to 50 saccharides, 40 to 50 saccharides, 42 to 50 saccharides, 44 to 50 saccharides, 46 to 50 saccharides, or 48 to 50 saccharides.

61. The biomaterial of claim 52, wherein the isolated heparin or heparan sulphate oligosaccharide has a chain length of 18 to 40 saccharides, optionally one of 20 to 40 saccharides, 22 to 40 saccharides, 24 to 40 saccharides, 26 to 40 saccharides, 28 to 40 saccharides, 30 to 40 saccharides, 32 to 40 saccharides, 34 to 40 saccharides, 36 to 40 saccharides, or 38 to 40 saccharides.

62. A method of treatment, the method comprising the step of administering the biomaterial of claim 52 to a subject in need thereof.

63. The method of claim 62, wherein the method of treatment comprises: a method of wound healing in vivo, the repair and/or regeneration of connective tissue, the repair and/or regeneration of bone, the repair and/or regeneration of bone in a mammal or a human, or the repair and/or regeneration of a broken bone.

64. The method of claim 62, wherein the biomaterial that is coated and/or impregnated with an isolated heparin or heparan sulphate oligosaccharide is provided as an implant or a prosthesis.

65. The method of claim 64, wherein the implant is a bone graft substitute.

66. The method of claim 62, wherein the method of treatment is a method of treating of a bone fracture, degenerated bone, aging bone, diseased bone, and/or bone injury.

67. The method of claim 62, wherein the method of treatment comprises the repair and/or regeneration of a long bone, short bone, flat bone, irregular bone, sesamoid bone, a skeletal bone, an appendicular bone, a bone of the pelvic skeleton, a bone of the cranio-facial region, a bone of the face, a bone of the mouth, a bone of the jaw and/or a bone of the vertebrae.

68. The method of claim 62, wherein the isolated heparin or heparan sulphate oligosaccharide is administered during surgery.

69. The method of claim 62, wherein the isolated heparin or heparan sulphate oligosaccharide is administered during dental, facial, or cranial surgery.

70. The method of claim 62, wherein the isolated heparin or heparan sulphate enhances BMP2-mediated ALP activity.

71. The method of claim 62, wherein the isolated heparin or heparan sulphate enhances BMP2-mediated Smad 1/5/9 phosphorylation.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0176] FIG. 1A to 1I. SPR competition binding assay sensorgrams. Representative sensorgrams generated from competitive binding experiments performed via SPR. BMP-2 (25 nM) was pre-incubated with a variety of heparin oligosaccharides (5 μg or 10 μg) and applied to a heparin-derivitised surface. SPR sensorgrams for heparin (A), dp4 (B), dp6 (C), dp8 (D), dp10 (E), dp12 (F), de-2-O-sulfated heparin (G), de-6-O-sulfated heparin (H) and de-N-sulfated heparin (I) display variable reduction in response over BMP-2 alone. All sensorgrams are representative of three independent experiments.

[0177] FIG. 2A to 2G. Chain length determines the ability of heparin to bind and stabilize BMP-2. Basic disaccharide structure of heparan sulfate and chondroitin sulfate (A). BMP-2 (20 ng) was incubated with heparin-Sepharose with or without glycosaminoglycans (B) or size defined heparin oligosaccharides (C) and bound BMP-2 detected via Western blot. (D) SPR sensorgram displaying the binding response generated by various concentrations (−6.25 nM, −12.5 nM, −25 nM, −50 nM, −100 nM) of BMP-2 binding to a heparin coated surface. (E) SPR-based competitive binding assays were performed by incubating heparin oligosaccharides (10 μg/mL) with BMP-2 (25 nM) and applying them to a heparin-coated SPR chip. (F, G) Differential scanning fluorimetry was performed by incubating BMP-2 (5 μM) in the presence or absence of heparin oligosaccharides (50 μM; -PBS, -BMP-2 alone, -heparin, -dp4, -dp6, -dp8, -dp10, -dp12). Fluorescence generated from the binding of SYPRO orange dye to the core of denatured BMP-2 was used to 17 determine relative complex stability vs. BMP-2+heparin. All data is representative of (B, C, D, F) or constitutes mean±S.D. (E. G) of three independent experiments. ****p <0.0001.

[0178] FIG. 3A to 3H. Size-exclusion chromatography of BMP-2 binding to heparin oligosaccharides. (A-D) 25 μM of each heparin oligosaccharides (dp6, dp8, dp10 or dp12) were eluted from a Superdex 200 column detected using absorption at 232 nm. (E-H) 25 μM BMP-2 and 25 μM of each heparin oligosaccharides (dp6, dp8, dp10 or dp12) were eluted from a Superdex 200 column and detected using absorption at 232 nm. Chromatographs are representative of three independent experiments.

[0179] FIG. 4A to 4E. BMP-2-induced Smad 1/5/9 phosphorylation, osteogenic gene transcription and ALP activity with heparin oligosaccharides. (A) C2C12 cells were stimulated with or without BMP-2 (100 ng/mL) and heparin oligosaccharides (dp4, dp6, dp8, dp10, and dp12; 5 μg/mL) for up to 72 h. Smad 1/5/9 phosphorylation was then detected via Western blot. C2C12 cells were stimulated with BMP-2 in the presence or absence of heparin or heparin oligosaccharides for 3 days, after which osteogenic gene transcription (B-D) or ALP activity (E) was determined. Data are represented as the mean±S.D. of three independent experiments. ****p <0.0001, ***p <0.001, **p <0.01. ns-p >0.05.

[0180] FIG. 5A to 5E. BMP-2 binding and thermal stability by desulfated heparins. (A) The structure of the main repeating disaccharide unit in heparin/HS chains. (B) Competition of BMP-2 (20 ng) binding to heparin Sepharose beads. (C) SPR-based competitive binding assays were performed by incubating selectively desulfated heparins (10 μg/mL) with BMP-2 (25 nM) and applying them to a heparin-coated SPR chip. (D-E) Differential scanning fluorimetry was performed by incubating BMP-2 (5 μM) with or without selectively desulfated heparins (50 μM) and SYPRO orange dye at increasing temperature (-PBS, -BMP-2 alone, -heparin, -de-2-O-sulfated, -de-6-O-sulfated, -de-N-sulfated). Fluorescence generated from the binding of SYPRO orange dye to the core of denatured BMP-2 was used to determine relative complex stability vs. BMP-2+heparin. Data is representative of (B. D) or constitutes mean±S.D. (C, E) of three independent experiments. ****p <0.0001; ns-p >0.05.

[0181] FIG. 6A to 6E. BMP-2-induced Smad 1/5/9 phosphorylation, transcription of osteogenic genes and ALP activity with selectively desulfated heparins. (A) C2C12 cells were stimulated with or without BMP-2 (100 ng/mL) and heparin or specific desulfated heparins (5 μg/mL) for up to 72 h. Smad 1/5/9 phosphorylation was then detected via Western blot. (B-E) C2C12 cells were stimulated with or without BMP-2 (100 ng/mL) in the presence or absence of heparin or desulfated heparin (5 μg/mL) and cultured for 3 days, after which osteogenic gene transcription (8-13) or ALP activity (E) were determined. Data are represented as the means±S.D, of three independent experiments. ****p <0.0001, ***p <0.001, ns-p >0.05.

[0182] FIG. 7A to 7B. BMP-2-induced osteogenic differentiation and mineralization with heparin oligosaccharides and selectively desulfated heparins. C2C12 cells were stimulated with or without BMP-2 (100 ng/mL) and heparin, heparin oligosaccharides or specific desulfated heparins (5 μg/mL) for 12 days. (A) Cells were stained with Alizarin red to detect the presence of calcium. (B) Alizarin red was extracted and quantified using spectrophotometry (absorbance at 405 nm) and normalized to the BMP-2 alone treatment group. Data is representative of (A) or represented as (B) the mean±S.D. of three independent experiments. ****p <0.0001, ns-p >0.05.

[0183] FIG. 8A to 8C. Establishment of controls for the rat ectopic bone formation assay. (A) Representative digital image, 2D x-rays and 3D μ-CT micrographs of samples harvested from the hind limb muscle of rats. The treatments were collagen sponges alone (Ctrl; n=4); or with 5 μg BMP-2 (BMP; n=4); or with 5 μg BMP-2+25 μg heparin (Hep; n=4). (B) The bone volume measurements (mm3) for the respective samples as determined by μ-CT analyses. Results are expressed as mean±S.E.M. (C) Representative histological sections showing the absence/presence of calcified bone matrix in the harvested samples. Staining consisted of Hematoxylin/Eosin, Modified Tetrachrome (blue: osteoid, red: bone) and von Kossa/McNeals (black: calcified deposits). BM: Bone marrow, B: Bone, C: Calcified matrix, scale bars-100 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

[0184] FIG. 9A to 9C. The assessment of dps8, 10 and 12 in a rat ectopic bone formation assay. (A) Representative digital images, 2D x-rays and 3D μ-CT micrographs of samples harvested from the hind limb muscle of rats. The treatments were collagen sponges with 5 μg BMP-2 and 25 μg of dps8 (n=4), 10 (n=4) or 12 (n=5). (B) The bone volume measurements (mm3) for the respective samples as determined by μ-CT analyses (dashed line represents bone volume for heparin treatment group). Results are expressed as mean±S.E.M. (C) Representative histological sections showing the presence of calcified bone matrix in the samples. Staining consisted of Hematoxylin/Eosin. Modified Tetrachrome (blue: osteoid, red: bone) and von Kossa/McNeals (black: calcified deposits). BM: Bone marrow, B: Bone, C: Calcified matrix, scale bars-100 μm.

[0185] FIG. 10A to 10C. The assessment of de-2-O-, de-6-O- and de-N-sulfated heparins in a rat ectopic bone formation assay. (A) Representative digital image, 2D x-rays and 3D μ-CT micrographs of samples harvested from the hind limb muscle of rats. The treatments were collagen sponges with 5 μg BMP-2 and 25 μg of de-2-O- (n-4), de-6-O- (n-4) or de-N-sulfated (n=5) heparins. (B) The bone volume measurements (mm3) for the respective samples as determined by p-CT analyses (dashed line represents bone volume for heparin treatment group). Results are expressed as mean±S.E.M. (C) Representative histological sections showing the presence of calcified bone matrix in the harvested samples. Staining consisted of Hematoxylin/Eosin, Modified Tetrachrome (blue: osteoid, red: bone) and von Kossa/McNeals (black: calcified deposits). BM: Bone marrow, B: Bone, C: Calcified matrix, scale bars-100 μm.

[0186] FIG. 11A to 11E. Binding, stabilization and activation of BMP-2 by other sulphated polysaccharides. (A) Representative SPR sensorgrams displaying the binding response generated by various sulfated polysaccharides (10 μg/mL) pre-incubated with BMP-2 (25 nM) and applied to a heparin-derivitised surface. (B) Normalized SPR data derived from (A) indicating the percentage of BMP-2 sequestered into solution by various sulphated polysaccharides. (C) Differential scanning fluorimetry was performed by incubating BMP-2 (5 μM) in the presence or absence of various sulfated polysaccharides (50 μM). (D) Fluorescence generated from the binding of SYPRO orange dye to the core of denatured BMP-2 was used to determine relative complex stability vs. BMP-2+heparin. (E) C2C12 cells were treated with BMP-2 (100 ng/mL) with or without various sulphated polysaccharides (5 μg/mL) for 3 days, after which protein was extracted and ALP activity was assessed. All data is representative of (A, C) or constitutes mean±S.D. (B, D-E) of three independent experiments. **p <0.01, ***p <0.001, ****p <0.0001.

[0187] FIG. 12A to 12E. Binding, stabilization and activation of BMP-2 by de-N-sulfated/re-N-acetylated dp12. (A) Representative SPR sensorgrams displaying the binding response generated by heparin, heparin dp12 or de-N-sulfated/re-N-acetylated heparin dp12 (10 μg/mL) pre-incubated with BMP-2 (25 nM) and applied to a heparin-derivitised surface. (B) Normalized SPR data derived from (A) indicating the percentage of BMP-2 sequestered into solution by heparin, heparin dp12 or de-N-sulfated/re-N-acetylated heparin dp12. (C) Differential scanning fluorimetry was performed by incubating BMP-2 (5 μM) in the presence or absence of heparin, heparin dp12 and de-N-sulfated/re-N-acetylated heparin dp12 (50 μM). (D) Fluorescence generated from the binding of SYPRO orange dye to the core of denatured BMP-2 was used to determine relative complex stability vs. BMP-2+heparin. (E) C2C12 cells were treated with BMP-2 (100 ng/mL) with or without heparin, heparin dp12 or de-N-sulfated/re-N-acetylated heparin dp12 (5 μg/mL) for 3 days, after which protein was extracted and ALP activity was assessed. All data is representative of (A, C) or constitutes mean±S.D. (B, D-E) of three independent experiments. ***p <0.001, ****p <0.0001, ns-p >0.05.

[0188] FIG. 13. Graph peaks relate to the crude size groups which were separated and pooled independently.

[0189] FIG. 14. Relative ALP activity of heparin fragments and HS3 fragments of different lengths.

[0190] FIG. 15. Sulfation analysis of HS3 fragments. Relative composition of NAc disaccharides, N-sulphated disaccharides, 6-O-sulphated disaccharides and 2-O-sulphated disaccharides in different size HS3 fragments is demonstrated.

[0191] FIG. 16. Disaccharide compositional differences between different length HS3 fragments shown in table form.

[0192] FIG. 17. Disacharide composition of HS3 fragments with different lengths is demonstrated.

[0193] FIG. 18. Sulfation comparisons between heparin dp12 and HS3.sup.>dp36. Heparin dp12 and HS3.sup.>dp36 are the most biologically active fragments derived from heparin and HS3. Relative composition of NAc disaccharides, N-sulphated disaccharides, 6-O-sulphated disaccharides and 2-O-sulphated disaccharides in different size HS3 fragments is demonstrated.

[0194] FIG. 19. Disacharide composition comparison of Heparin dp12 and HS3.sup.>dp36, the most biologically active fragments derived from heparin and HS3.

[0195] FIG. 20. Disacharide compositional comparisons between heparin dp12 and HS3>dp36. These are the most biologically active fragments of Heparin and HS3 and have different disaccharide compositions and shown in the table.

EXAMPLES

[0196] In the following examples, the inventors describe the generation of heparan sulfate and heparin oligosaccharides with variable sizes. Additionally, the inventors demonstrate that heparan sulfate and heparin oligosaccharides fragments with reduced chain lengths can function as effectively as full length molecules.

Example 1: Methods to Determine Minimum Structural Requirements for BMP-2-Binding of Heparin Oligosaccharides

[0197] 1.1. Materials

[0198] All cell culture reagents, chemicals and heparin were purchased from Sigma-Aldrich (U.S.A.). Recombinant BMP-2 was purchased from R&D Systems Inc. (U.S.A.). Smad 1/5/8 antibody was purchased from Santa Cruz Biotechnology (Cat. #sc-6301-R; U.S.A.). Phospho-smad1/5/9 antibody (equivalent to phospho-smad1/5/8) was purchased from Cell Signaling Technologies (Cat. #13820: U.S.A.). Actin antibody (Cat. #MAB1501R) and protease inhibitor cocktail III were purchased from Merck-Millipore (U.S.A.). OIAzol lysis reagent was purchased from Qiagen (Germany). SYPRO orange. Superscript® Vilo™ cDNA synthesis kit, TaqMan® gene expression assays and TaqMan® Fast universal PCR mastermix, Pierce BCA protein assay kit, SuperSignal West Pico Chemiluminescent substrate, N-hydroxysuccinimide (NHS)-biotin and Zeba® spin 7 kDa MWCO desalting columns were purchased from Thermo-Fischer (U.S.A.). Size-defined heparin oligosaccharides (dp4-dp20) and selectively desulfated heparins were purchased from Iduron (U.K.). The C2C12 murine myoblast cell line was purchased from the American Type Culture Collection (ATCC). Hyperfilm, Superdex 200 HR (10×300 mm) and Sensor Chip SA were purchased from GE Healthcare (Sweden). Polycaprolactone (PCL) tubes (dimensions of 4.5 mm inner diameter, 3 mm height and 1 mm wall thickness) were purchased from Osteopore International Pte Ltd (Singapore). Collagen sponges were obtained from Integra LifeSciences Corp (U.S.A.) and measured 7×21×5 mm. Each sponge was cut evenly into 6 pieces with a sterile blade prior to implantation.

[0199] 1.2. Surface Plasmon Resonance BMP-2 Competitive Binding Assay

[0200] Interactions between BMP-2 and heparin oligosaccharides were measured via competitive inhibition of BMP-2 binding to a heparin-coated sensor chip using surface plasmon resonance, as described by Lee et al [27]. Briefly, 20 mg heparin was biotinylated at free amine groups using 8.6 μM NHS-biotin in dimethyl sulfoxide, after which excess unreacted NHS-biotin was removed by passing the sample through two 7 kDa molecular weight cut-off Zeba spin desalting columns. Using the inbuilt immobilization program on a Biacore T100 SPR system (GE healthcare), a sensor chip SA (GE healthcare) was coated with heparin-biotin in HBS-EP 0.05% buffer (150 mM NaCl, 10 mM HEPES, 3 mM EDTA, 0.05% (v/v) Tween-20, pH 7.4) at a flow rate of 30 μL/min until ˜40 response units (R.U.) were achieved (where 1 R.U. is equal to −1 μg of heparin/mm2). Dosing experiments were performed with BMP-2 with a range of concentrations from 6.25 nM to 100 nM, after which a dose of 25 nM was selected for competitive inhibition experiments. Heparin oligosaccharides were used at a concentration of 10 μg/mL in HBS-EP 0.1% buffer (HBS-EP with 0.1% (v/v) Tween-20). BMP-2 alone or BMP-2+heparin were applied to the chip for 120 sat 30 μL/min, followed by a 600 s dissociation period of HBS-EP 0.1% alone, after which the heparin surface was regenerated by two injections of 2 M NaCl in HBS-EP 0.1% for 60 s at 30 μL/min. The response was measured as a function of time at 25° C. R.U.s for the heparin surface were determined by subtracting the R.U. of the control (uncoated) flow channel from those of the heparin-biotin-coated flow channel. Representative sensorgrams from all competitive binding experiments may be found in supplementary information (FIG. 1). Results were normalized to the response of BMP-2 alone (100% response) and represented as the percentage reduction in response units vs. BMP-2 alone. Data constitutes the mean±S.D. of three independent experiments.

[0201] 1.3. Differential Scanning Fluorimetry/BMP-2 Thermal Stability Assay

[0202] The ability of heparin oligosaccharides to improve the thermal stability of BMP-2 was assessed via differential scanning fluorimetry (DSF). Briefly, BMP-2 (5 μM), heparin oligosaccharides (50 μM), urea (5 M), HCl (400 μM). SYPRO orange (×50) and PBS were gently mixed and aliquoted into triplicate wells of a 96-well optical PCR plate (Axygen). Experiments were performed using a Quantstudio 6 real time PCR machine (Applied Biosciences) using the following heating cycle; 120 s incubation at 31° C. followed by 0.5° C. increases every 20 s to 81° C. Data was acquired using detection settings for TAMRA dye (γex 560 nm; γem 582 nm). BMP-2 melting temperature was determined by an observable peak in fluorescence emission generated by the binding of SYPRO dye to the core of the denatured protein. The highest temperatures determined from the first derivative of the melt curve from each replicate were selected and the relative stabilizing effect of each oligosaccharide vs. heparin was assessed using the following equation:

[00001]$\frac{\mathrm{TmX}-\mathrm{TmBMP}2}{\mathrm{Tm}\mathrm{heparin}-\mathrm{TmBMP}2}$

[0203] Where Tm=melting temperature, X=oligosaccharide+BMP-2, BMP2=BMP-2 alone and heparin=heparin+BMP-2). Data is represented as the mean±S.D. of three independent experiments.

[0204] 1.4. Size-Exclusion Chromatography

[0205] A Superdex 200 HR column (300×10 mm, GE Healthcare) was equilibrated using a Dionex ICS 3000 series High Performance Liquid Chromatography (HPLC) system at a flow rate of 0.5 ml/min with running buffer (10 mM HEPES, pH 7.2, and 150 mM NaCl). Heparin fragments (25 μM) were incubated in the presence or absence of BMP-2 (25 μM) for 15 min at room temperature in running buffer, after which samples were loaded onto the column and eluted under isocratic flow at 0.5 ml/min. Elution of samples was monitored via absorbance at 232 nm (heparin) and 280 nm (BMP-2). All chromatographs are representative of three independent experiments.

[0206] 1.5. Detection of Phosphorylated Forms of Smad 1/5/9 by Western Blotting

[0207] C2C12 murine myoblast cells were cultured in DMEM, 10% FCS and 100 U/mL penicillin/streptomycin at 37° C. in 5% CO2. For experiments, cells were seeded at 2×104 cells/cm2 in tissue culture treated 12-well plates. After 24 h, cells were washed and media was replaced with treatment media (maintenance media with 5% FCS) with or without BMP-2 (100 ng/mL) and heparin, heparin oligosaccharides or desulfated heparins (5 μg/mL). At the indicated time points (24, 48 and 72 h), cells were washed with PBS and lysed with RIPA buffer in the presence of protease inhibitors (Merck-Millipore). Total protein was quantified using the BCA assay and subsequently separated by SDS-PAGE (5 μg total protein per condition). Proteins were then transferred to nitrocellulose membranes and blocked for 1 h in blocking buffer (Tris-buffered saline containing 5% (w/v) non-fat dry milk and 0.05% (v/v) Tween 20). Incubation with primary antibodies diluted at 1:1000 (pSmad 1/5/9), 1:500 (Smad 1/5/8) or 1:5000 (actin) was carried out overnight at 4° C. in blocking solution. Membranes were washed three times with Tris-buffered saline containing 0.05% (v/v) Tween 20 and incubated with IgG-specific peroxidase-conjugated secondary antibodies, diluted 1:10000 in blocking buffer. Blots were then washed and developed using SuperSignal West Pico Chemiluminescent substrate (Thermo Scientific) on Hyperfilm (GE Healthcare) and scanned. Blots are representative of three independent experiments.

[0208] 1.6. Analysis of Osteogenic Transcript Expression Via Quantitative Real Time PCR

[0209] C2C12 cells were maintained and seeded as described above. Cells were treated with or without BMP-2 (100 ng/mL) with heparin, heparin oligosaccharides, or selectively desulfated heparins (5 μg/mL). The cells were cultured in treatment media for 3 days, after which total RNA was harvested using OIAzol lysis reagent (Qiagen) according to manufacturers instructions. Total RNA was quantified via Nanodrop 2000 and 1 μg total RNA was reverse transcribed to generate complementary DNA (cDNA) using SuperScript Vilo (Thermo-Fisher) according to manufacturer's instructions. Quantitative real-time PCR (qPCR) was performed using a Quantstudio 6 real-time PCR machine, using 40 ng of cDNA per reaction in conjunction with TaqMan® gene expression assays (Thermo-Fisher). Transcription of osteogenesis-associated genes of interest were analyzed using the following TaqMan® gene expression assays: alpl (Mm00475834_m1), sp7 (Mm04209856_m1) and runx2 (Mm00501584_m1). Ribosomal RNA 18s (Mm04277571_s1) was used as an internal control. Data was analyzed using the ΔΔCt method and normalized to treatment with BMP-2 alone. Data is expressed as mean fold change±S.D. of three independent experiments.

[0210] 1.7. Alkaline Phosphatase Activity Assay

[0211] C2C12 cells were maintained as described above and seeded at 2×104 cells/cm2 in tissue culture treated 24-well plates. The cells were cultured in treatment media for 3 days, after which total protein was extracted and ALP activity was determined. Briefly, cells were washed with PBS and total protein extracted with RIPA buffer containing a protease inhibitor cocktail. Total protein concentration was determined using the BCA assay, then 7.5 μg of total protein per condition was combined with p-nitrophenylphosphate (Thermo-Fisher). Absorbance was measured at 405 nm via spectrophotometry and expressed as relative ALP activity normalized to the BMP-2 alone treatment group. Data represents mean±S.D. of three independent experiments.

[0212] 1.8. Osteogenic Differentiation and Mineralization

[0213] C2C12 cells were maintained as described above and seeded at 5×103 cells/cm2 in tissue culture treated 12-well plates. Cells were cultured in osteogenic media (DMEM low glucose, 5% (v/v) FCS, 100 U/mL penicillin/streptomycin, 10 mM β-glycerophosphate and 50 μg/mL ascorbic acid 2-phosphate) with or without BMP-2 (100 ng/mL) and heparin variants (5 μg/mL) for 12 days, with media being replenished every three days. Cells were washed with PBS and fixed with ice cold methanol for 20 min at −20° C. After fixation, cells were washed with water and stained with Alizarin red solution (0.1% (w/v), pH 4.3) for 20 min at room temperature with gentle agitation. Cells were then washed three times with water and imaged using a scanner. Alizarin red dye was extracted with 10% (Of) acetic acid, neutralized with 10% (w/v) ammonium hydroxide and quantified using spectrophotometry (absorbance at 405 nm). Images are representative of at least three independent experiments and quantified Alizarin red stain represents mean±S.D. of three independent experiments.

[0214] 1.9. Ectopic Bone Formation Assay

[0215] Thirteen female, Sprague Dawley rats weighing 120-150 g had four hind limb muscle pockets surgically created, two per limb [48]. Each pocket was randomly filled with one of the following treatments; (1) Polycaprolactone tube (PT), (2) PT+collagen sponge (CS) (Ctrl), (3) PT+CS+BMP-2 (5 kg), (4) PT+CS+heparin (25 μg)+BMP-2 (5 μg). (5) PT+CS+dp8 (25 μ9)+BMP-2 (5 μg), (6) PT+CS+dp10 (25 μg)+BMP-2 (5 kg), (7) PT+CS+dp12 (25 kg)+BMP-2 (5 μg), (8) PT+CS+de-2-O sulfated heparin (25 μg)+BMP-2 (5 μg) (9) PT+CS+de-6-O sulfated heparin (25 μg)+BMP-2 (5 kg, (10) PT+CS+de-N-sulfated heparin (25 μ9)+BMP-2 (5 μg). There were 4 replicates for groups (1-3) and 5 replicates for groups (4-10). The doses and ratio of BMP-2 and heparin were based on those used in previous studies [22, 32]. Rats were sacrificed and specimens harvested 8 weeks post-implantation. All samples were assessed with 2D x-rays, μ-CT and histology to assess the extent of bone mineral deposition.

[0216] 1.10. Surgical Methods

[0217] All surgical procedures were performed under aseptic conditions and in strict accordance to the guidelines of A*STAR's Institutional Animal Care and Use Committee. General anesthesia was established by the administration of isoflurane, Two transverse incisions, 1 cm each, were made over each hind limb muscle. Pockets were then created by blunt dissection of the muscle, parallel to the longitudinal-axis of muscle fibers. The specimens were then implanted into these pockets. The incisions were then closed in both the muscle and skin layers. Prophylactic antibiotics (Baytril, 10 mg/kg) and analgesics (Buprenorphine, 0.01-0.05 mg/kg) were administered subcutaneously for three days post-operation.

[0218] 1.11. 2D Radiographic Analysis

[0219] 2D images of muscle pockets were captured immediately post-operation and at week 8 using an Imaging Radiographic System (MUX-100, Shimadzu). Digital micrographs were subsequently generated from the x-rays.

[0220] 1.12. 3D μ-CT Analysis

[0221] A μ-CT scanner (Skyscan 1076: Skyscan, Belgium) was utilized to scan the harvested specimens (resolution=35 μm; scanning width=68 mm) as per our previous methods [34, 35]. Scanner voltage and current were set to 104 kV and 98 μA respectively. Cone-Beam CT-reconstruction® A Sasov software (Skyscan) was used to process the isotropic slice data and convert into 2D images. Mimics 13.1 software (Materialise. Belgium) was then used to analyze and remodel data in 3D, using the same number of slices and cylindrical region of interest (ROI)—for each specimen. The total bone volume within the ROI was quantified by assigning a pre-determined threshold for total bone content. Specimens containing BMP-2, which exhibited zero bone growth via x-ray and μ-CT (≤0.05 mm.sup.3) were excluded from further analysis. Data represents mean±S.E.M. of total bone volume (mm3).

[0222] 1.13. Histological Evaluation

[0223] Specimens were fixed in 10% formalin (neutral buffered) under vacuum for one week. For paraffin histology, specimens were decalcified for two weeks in 30% formic acid at room temperature. The specimens were then processed with a vacuum infiltration processor (Sakura Finetek, Japan) using a 14 h program, followed by dehydration, clearing, and finally embedding in Paraplast® paraffin wax (Thermo Scientific). Paraffin blocks were sectioned longitudinally at 5 μm using a rotary microtome (Leica Microsystems, Germany), and left to dry on positively-charged microscope slides. These slides were subsequently stained with hematoxylin & eosin and modified tetrachrome. Both stains allow for the identification of bone marrow and bone based on its morphology and cellular details. A blue stain and red patches represent osteoid and bone deposition respectively for the modified tetrachrome method. For resin histology, specimens were dehydrated through an ethanol series, followed by processing and embedding in methylmethacrylate. Transverse sections of 5 μm's were cut and stained with von Kossa/MacNeals, for the positive identification of calcified deposits (which stained black). All sections were examined with an Olympus Stereo (SZX12) and upright (BX51) fluorescence microscopes.

[0224] 1.14. Statistical Methods

[0225] All data is represented as the mean±S.D. of at least three independent experiments unless otherwise stated. For statistical analysis, one and two-way analysis of variance (ANOVA) with Tukey's post hoc analysis was performed using Prism 7 software (GraphPad, San Diego, USA). P <0.05 was considered significant. The following symbols were used to indicate p-value range; * p <0.05; ** p <0.01; *** p <0.001; **** p <0.0001; ns—not significant (p >0.05).

Example 2: Minimum Structural Requirements for BMP-2-Binding of Heparin Oligosaccharides—Results

[0226] 2.1. Effect of Heparin Oligosaccharide Length on Competitive Binding of BMP-2 to Heparin

[0227] To assess the minimum saccharide length requirement for binding of heparin to BMP-2, we subjected heparin oligosaccharides (dp4, dp6, dp8, dp10, dp12, dp14, dp16, dp18 or dp20: the structure of a dp2 is illustrated in FIG. 2A) to SPR competitive binding assays. When a range of doses of BMP-2 were applied to a heparin-coated SPR chip, abundant response was observed (FIG. 2B). Pre-incubation with heparin resulted in 97% of the BMP-2 being sequestered in solution, preventing binding to the heparin-coated surface (FIG. 2 C). Dp4 were unable to sequester BMP-2 into solution, suggesting they are incapable of preventing BMP-2 from binding the heparin-coated surface. When dp6 and dp8 were pre-incubated with BMP-2 prior to application to the heparin-coated chip, a reduction in R.U. was observed (FIG. 2C). Dp6 and dp8 sequestered 4% and 24% of BMP-2 respectively (FIG. 2C). Dp10, dp12, dp14 and dp16 further sequestered BMP-2 in solution, binding 36%, 61%, 76% and 80% respectively (FIG. 2C). Finally, dp18 and dp20 sequestered 85% and 82% of BMP-2 in solution respectively, quantities comparable to those sequestered by heparin (p >0.05).

[0228] 2.2. Heparin Oligosaccharides of Increasing Length Enhance the Thermal Stability of BMP-2

[0229] We further investigated the interaction between heparin oligosaccharides and BMP-2 by performing DSF, an assay which enabled us to investigate the effect of heparin oligosaccharides on the thermal stability of BMP-2. FIG. 20 displays the shift in peak fluorescence toward a higher temperature upon the addition of oligosaccharides of increasing size (FIG. 2D). FIG. 2E displays the relative increase in the thermal stability of BMP-2 with the addition of native heparin and heparin oligosaccharides ranging between dp4 and dp20. Dp4 and dp8 offered minimal enhancement in BMP-2 thermal stability, whereas dp8 and dp10 enhance BMP-2 thermal stability to half that achieved by native heparin (FIG. 2E). Dp12 offered a further increase in thermal stability over the smaller fragments, and further increases in stability were observed for dp14, dp16 and dp18. Dp20 offered further increases in thermal stability, comparable with native heparin. Statistical analysis using one-way ANOVA revealed that oligosaccharide size had a significant effect on BMP-2 thermal stability (p <0.0001). Further post hoc comparisons between individual groups indicated that the stabilizing effect of dp4-dp18 on BMP-2 was significantly less than that of native heparin (p <0.0001), with only a dp20 offering comparable stability to heparin (p >0.05).

[0230] 2.3. Size-Exclusion Chromatography of BMP-2 and Heparin Oligosaccharides

[0231] We next investigated the ability of oligosaccharides to bind BMP-2 using a size-exclusion chromatographic technique. FIG. 3 (A-D) displays the dp6-12 peak elution positions. After incubation of heparin oligosaccharides, it is evident that the elution position of dp6 or dp8 saccharides remained unaffected by BMP-2 (FIG. 3E-F); indicating that minimal binding occurred between BMP-2 and dp6 or dp8 fragments. In contrast, the elution position of the dp10 saccharide was split equally into BMP-2-bound and -unbound peaks (FIG. 3G), again indicating this is the minimal heparin length required for BMP-2 binding. When BMP-2 was incubated with the dp12 preparation, the elution position of the single major peak was significantly shifted (FIG. 3H). These data confirmed that dp10 is the minimal heparin oligosaccharide length required for significant levels of BMP-2 binding, and dp12 for maximal levels. For subsequent in vitro studies, dp4 to dp12 were used.

[0232] 2.4. Heparin Oligosaccharide Length Influences BMP-2-Induced Signaling and Differentiation of C2C12 Cells

[0233] We next examined the time course changes induced by BMP-2 and oligosaccharides (dp4-dp12) in the phosphorylation of the specific downstream BMP-2 intracellular effector Smad 1/5/9. In the absence of additional heparin oligosaccharides, the levels of BMP-2-induced Smad 1/5/9 phosphorylation were detectable at 24 and 48 h; after 72 h, Smad 1/5/9 phosphorylation was no longer detectable in cultures exposed to BMP-2 alone (FIG. 4Ai-iii). Smad 1/5/9 phosphorylation levels were similar across all treatment groups at 24 and 48 h (FIG. 4Ai-ii). At 72 h, Smad 1/5/9 phosphorylation had decreased progressively in cultures treated with shorter oligosaccharides (dp4, dp6 or dp8; FIG. 4Aiii). Cultures treated with heparin or dp12 fragments displayed the highest levels of Smad 1/5/9 phosphorylation (FIG. 4Aiii). These data confirm that oligosaccharides ≥dp10 in length prolong and maintain BMP-2-induced Smad 1/5/9 phosphorylation. We next compared the bioactivity of heparin oligosaccharides by assaying BMP-2-induced up-regulation of osteogenic gene transcripts and ALP activity in C2C12 myoblast cells. We chose to assess changes in transcript level of alpl, runx2 and sp7, as all are markers of osteogenic differentiation. Additionally we chose to assess ALP activity as ALP is a key marker of osteogenic differentiation. Alone, heparin and heparin oligosaccharides did not induce expression of osteogenic genes alpl, sp7 and runx2, or ALP activity (FIG. 4B-E). However, when cells were exposed to 100 ng/ml of BMP-2, in the presence of heparin, a rapid induction of osteogenic gene transcription and ALP activity was observed (FIG. 4B-E). Dp4 and dp6 failed to substantially upregulate BMP-2-induced gene transcription or enhance ALP activity over BMP-2 alone (FIG. 4B-E). Dp8 upregulated gene transcription and enhanced ALP activity, but to a lesser extent than native heparin (FIG. 4B-E). However, dp10 enhanced BMP-2-induced ALP activity to the levels of native heparin (FIG. 4E, p >0.05) and dp12 are capable of significantly enhancing BMP-2-induced ALP activity over native heparin (p <0.01). Dp12s also enhanced osteogenic gene transcription, but not to the level of native heparin in the case of Alpl and Sp7 (FIG. 4 B, D). Thus the minimum oligosaccharide length required for maintenance of BMP-2-induced transcription of osteogenic genes and enhancement of ALP activity is a dp12.

[0234] 2.5. Selectively Desulfated Heparin Interactions with BMP-2

[0235] The structure of the disaccharide units in heparin is depicted in FIG. 5A. Heparin chains contain an abundance of N-, 2-O-, and 6-O-sulfate groups, as well as the rarer 3-O-sulfate group, and these substitutions (when organized into specific sequences or domains) are responsible for interaction with heparin/HS-binding proteins. To determine the importance of specific sulfate groups of heparin/HS chains in the binding of BMP-2, we performed SPR competitive binding experiments to ascertain how well selectively desulfated heparins can out-compete surface heparin for the binding of BMP-2. Heparin and de-2-O-sulfated heparin sequestered a substantial amount of BMP-2 into solution (73%) in SPR competition assays (FIG. 5B). As observed in the GAG binding plate assay, de-6-O-sulfated heparin displayed a marginally lower affinity to BMP-2, sequestering 63% of BMP-2 in solution (FIG. 5B). Finally, de-N-sulfated heparin was unable to bind and sequester any BMP-2 into solution, however, re-N-acetylation of the free amine group rescued BMP-2 binding, resulting in 51% of BMP-2 being sequestered into solution (FIG. 5B).

[0236] These data indicate a hierarchy of necessity, wherein N-sulfation is essential for BMP-2 binding, with 6-O-sulfation partially contributing and 2-O-sulfation only minimally.

[0237] 2.6. Effect of Selectively Desulfated Heparins on the Thermal Stability of BMP-2

[0238] We further investigated the interactions of selectively desulfated heparins and BMP-2 by using DSF. Pre-incubating BMP-2 with selectively desulfated heparins resulted in a decrease in the melting temperature of BMP-2 compared to that with heparin, evident by a shift in peak fluorescence to a lower temperature (FIG. 5C). The loss of 2-O and 6-O-sulfation resulted in a ˜10% and ˜20% reduction in the thermal stabilizing effect of heparin, respectively (FIG. 5D). Loss of N-sulfation further reduced the thermal stabilizing effect of heparin, to ˜33% of that of native heparin (FIG. 5D). Re-N-acetylation of de-N-sulfated heparin resulted in an improvement in the thermal stabilizing effect, from 33% to 71% (FIG. 5D). Statistical analysis via one-way ANOVA revealed that sulfation contributes significantly to the thermal stabilizing effect of heparin toward BMP-2 (FIG. 5D; ****p <0.0001). The loss of 6-O-sulfation results in significant reduction in stabilizing effect (***P <0.001), however the of 2-O-sulfation did not result in a significant reduction in the stabilizing effect of heparin (ns-p >0.05). The loss of N-sulfation resulted in a significant reduction in stabilizing effect (****p <0.0001); subsequent re-N-acetylation improved the stabilizing effect over de-N-sulfated species, but to a level that is still significantly lower than that of native heparin (****p <0.0001). These data once again confirm a hierarchy of importance with regards to sulfation. N-sulfation plays an essential role in the thermal stabilizing effect of heparin on BMP-2, while 6-O-sulfation offers a partial contribution and 2-O-sulfation offering a minimal contribution.

[0239] 2.7. Effect of Selectively Desulfated Heparins on BMP-2-Induced Osteogenic Gene Transcription and ALP Activity

[0240] We next studied the importance of specific sulfate groups within heparin/HS chains in BMP-2-induced Smad 1/5/9 phosphorylation, transcription of osteogenic genes and enhancement of ALP activity assay. Similar to observations with sized heparin oligosaccharides, phosphorylation levels of Smad 1/5/9 were not affected within 24 h by heparin and selectively desulfated heparins (FIG. 6Ai); however, at 48 h. the levels decreased in cultures treated with de-N-sulfated or de-N-sulfated/re-N-acetylated heparins (FIG. 6Aii). After 72 h, cultures treated with heparin, de-2-O-sulfated or de-6-O-sulfated heparin displayed the highest levels of Smad 1/5/9 phosphorylation (FIG. 6Aiii). Smad 1/5/9 phosphorylation was barely detectable in cultures treated with BMP-2 alone or BMP-2 with de-N-sulfated and de-N-sulfated/re-N-acetylated heparins after 72 h (FIG. 6Aiii). Heparin and selectively de-sulfated heparins alone had no effect on gene transcription (FIG. 6B-D) or ALP activity in C2C12 cells (FIG. 6E). However, when cells were treated with a combination of BMP-2 (100 ng/ml) and heparin (5 mg/ml), the induction of alpl, sp7 and runx2 transcription and ALP activity was greatly enhanced (FIG. 6B-E). De-2-O-sulfation of heparin did not significantly affect the enhancement of alpl and runx2 transcription (FIG. 68, C; p >0.05), but resulted in a significant reduction in sp7 transcripts and ALP activity (FIG. 6D, E; p <0.0001). De-6-O-sulfation or de-N-sulfation and subsequent re-N-acetylation of heparin significantly reduced BMP-2-induced alpl and sp7 transcription and ALP activity (FIG. 68-E); p <0.0001). These data clearly indicate the essential role of N-sulfation in enhancing BMP-2-induced Smad 1/5/9 phosphorylation, osteogenic gene transcription and ALP activity in C2C12 cells, more so than 6-O- and especially 2-O-sulfation.

[0241] 2.8. Effect of Heparin Oligosaccharides on BMP-2-Induced Osteogenic Differentiation and Mineralization

[0242] We further investigated the length and sulfation requirements within heparin chains by employing an osteogenic differentiation assay over the course of 12 days. We observed that BMP-2 alone (100 ng/mL) was not sufficient to induce mineralization in C2C12 cells, as indicated by calcium deposition detected by Alizarin red stain (FIG. 7A-B). The addition of heparin and BMP-2 lead to extensive mineralization, as evident from the presence of Alizarin red staining (FIG. 7A-B). Addition of heparin oligosaccharides dp4, dp6 and dp8 did not enhance mineralization in the presence or absence of BMP-2 (FIG. 7A-B). Addition of heparin dp10 with BMP-2 increased mineralization, although not to the level of heparin (p <0.0001), whilst addition of heparin dp12 enhanced mineralization to similar levels of native heparin (ns; p >0.05; FIG. 7A-B). De-N-sulfated heparin was incapable of enhancing mineralization, and de-6-O-sulfated heparin only minimally enhanced mineralization (FIG. 7A-B). De-2-O-sulfated heparin enhanced mineralization to the same extent as native heparin (ns; p >0.05; FIG. 7A-B). Re-N-acetylation of de-N-sulfated heparin partially rescued the ability of heparin to enhance BMP-2-mediated mineralization, but not to the level of de-2-O-sulfated heparin (FIG. 7A). These data indicate that a minimum length of a dp10 (optimally a dp12) and N-sulfation (optimally N- and 6-O-sulfation) are required for heparin to enhance BMP-2-mediated osteogenic differentiation in C2C12 cells.

[0243] 2.9. Ectopic Bone Formation

[0244] The comprehensive in vitro data strongly suggests that lengths of at least dp10 containing essential N-sulfated motifs are crucial for the biological activation of BMP-2 by heparin. To widen the validity of these observations, selected oligosaccharides were next tested in an in vivo rat ectopic bone-forming model. All rats survived the surgeries and recovered uneventfully. PCL tubes were used in the study to allow for straightforward implant retrieval and did not contribute to any bone formation (data not shown). FIG. 8 shows the combined results for the positive and negative controls. The digital, 2D x-ray and 3D μ-CT micrographs correlate well and demonstrated increased amounts of mineralization when BMP-2 was present in the implant (Ctrl, BMP and Hop; FIG. 8A). Bone volume measurements revealed a similar trend (FIG. 88). BMP-2 alone resulted in ˜16-fold increase in bone volume compared to control (Ctrl), while treatment with BMP-2 complexed with native heparin resulted in ˜0.2-fold increase over BMP-2 alone. One sample from the BMP-2/heparin group displayed no bone formation via x-ray and μ-CT, therefore was excluded from further analysis. The difference between BMP-2 and BMP-2/heparin groups is comparable to that observed in a previous study using a similar ectopic model [49]. Paraffin and resin histology were both performed to confirm the presence of bone-like tissue. No bone was detected in controls, unlike the BMP-2 and BMP-2/heparin treatments, which resulted in the infiltration of bone marrow and the deposition of a calcified bone matrix (with osteocytes clearly visible within lacunae) as observed in H&E-, modified tetrachrome- and von Kossa/McNeals-stained sections (FIG. 8C).

[0245] Once the controls were established, the in vivo performance of BMP-2 complexed with dp8, 10 and 12 saccharides were investigated (FIG. 9). Once again there was good correlation between the digital, 2D x-ray and 3D μ-CT micrographs (FIG. 9A). One sample from each of the dp8 and dp10 groups displayed no bone formation via x-ray and μ-CT, therefore they were excluded from further analysis. The dp8 treatment resulted in less bone deposition than dps 10 and 12. This trend was supported by bone volume measurements that revealed a ˜1.7-fold increase with dp12 as compared with dp8 (FIG. 9B). Histological sectioning confirmed the deposition of a calcified bone matrix; this was interspersed within the bone marrow for all three groups, with the dp8 group displaying the least overall amount of bone tissue (FIG. 9C). These data indicate a clear trend that increasing chain length enhances BMP-2-induced bone formation in vivo.

[0246] Finally, we contrasted the in vivo effectiveness of BMP-2 complexed with de-2-O-, de-6-O- and de-N-sulfated heparins (FIG. 10). One sample from each of the de-2-O-S and de-6-O-S groups displayed no bone formation via x-ray and μ-CT, therefore they were excluded from further analysis. The digital, 2D x-ray and 3D μ—CT micrographs showed that de-2-O- and de-6-O-sulfated oligosaccharides resulted in enhanced mineral deposition compared to those de-N-sulfated (FIG. 10A). This observation corresponded to bone volume measurements, where the former displayed an increase in bone volume compared to the latter (FIG. 10B). Meanwhile, the loss of 2-O- and 6-O-sulfate groups did not affect the in vivo efficacy of these heparin variants, as indicated by comparable bone volume measurements between the two groups. Histological sections mirrored this trend, and although calcified bone matrices with bone marrow elements were observed for all treatments, the de-N-sulfated group had noticeably reduced amounts of new bone tissue (FIG. 10C).

Example 3: Minimum Structural Requirements for BMP-2-Binding of Heparin Oligosaccharides—Discussion

[0247] Information regarding the precise structure and composition of the bioactive domains of HS remains essential if reliable HS-based therapeutics are to be formulated. This knowledge, detailing the structural and functional relationships between HS and proteins, may also aid in the eventual creation of synthetic HS analogues, which could eventually negate the requirement for animal-derived products. The work here describes our initial attempts to more closely define the essential elements of BMP-2-activating heparin/HS domains, as we have previously with TGF-β1 [36]. The results of this study indicate a minimal chain length of ten monosaccharides (dp10, decasaccharide), and the central importance of N-sulfation in the binding of BMP-2 and potentiation of its biological activity, both in vitro and in vivo. These data regarding sulfation are in agreement with previous studies; these indicated a hierarchy of importance in heparin sulfation for effective binding of BMP-2 and potentiation of its biological activity [37, 38]. Specifically, data presented in these studies and the current study highlight the importance of N-sulfation. Such information on specific requirements for size and sulfation may in turn be incorporated into artificial HS analogues, as synthetic techniques begin to mature [39, 40].

[0248] Here we first performed a competition assay to more systematically determine the interaction between BMP-2 and various GAG subclasses, BMP-2 has been previously reported to strongly interact with heparin and HS GAGs. In our previous study, we observed little or no binding of BMP-2 to CS-A, CS-C. CS-B (dermatan sulfate) or keratan sulfate (KS) [34]. Indeed, we further confirmed that CS-A, DS and KS bound little BMP-2 and did not enhance BMP-2-mediated ALP activity in C2C12 cells (FIG. 11). Moreover, dextran sulfate, a large and highly charged branching polymer was able to bind BMP-2 with high affinity, but inhibited BMP-2 bioactivity in vitro (FIG. 11). Previous studies have indicated that BMP-7 and FGF-1 interact with heparin and HS, but not CS, whereas FGF-2 can bind heparin and CS-E polysaccharides with similar binding affinities [17, 41].

[0249] A number of heparin oligosaccharides of defined size were employed to determine the importance of chain length on BMP-2 binding by SPR competition and size-exclusion chromatography assays. The results demonstrated that heparin fragments of 3-4 disaccharides displayed a limited ability to bind BMP-2, and that binding gradually increased through dp6 and dp8. Longer oligosaccharides, such as dp10 and dp12 displayed high binding to BMP-2, but dp18 provided maximal binding, equivalent to that observed with heparin. Size-exclusion chromatography results confirmed the data acquired from SPR competition assays: dp12 bound large amounts of BMP-2. We additionally performed DSF assays to establish the importance of oligosaccharide length on the thermal stability of BMP-2. These data revealed that increasing chain length resulted in increased thermal stability of BMP-2, with a dp12 offering a substantial increase in thermal stability over BMP-2 alone and a dp20 offering thermal stability equivalent to that of heparin. Together, these data demonstrate a minimal requirement of a dp10, optimally a dp12, and maximally a dp16 for the binding of heparin to BMP-2.

[0250] Key experiments have firmly established that a particular 3-O-pentasaccharide within heparin is the minimal size required for antithrombin III binding and activity [28, 42-44]. In contrast, a dp8 was the shortest heparin fragment that could subtend FGF-1 and FGF-2 binding [45, 46], although dp10s were required for optimum proliferative activity [47, 48]. Similarly, the minimum size requirement for FGF-7 and FGF-10 binding to dermatan sulfate is a dp10, although larger oligosaccharides (dps14-20) are required for optimum activity [49. 50]. In addition, we have previously confirmed that oligosaccharides of dp18 and above are required for optimal binding of TGF-β1; furthermore oligosaccharides of dp14 and above promote TGF-β1-induced biological activity in human mesenchymal stem cells (MSCs) [36].

[0251] Previous studies have demonstrated that heparin is capable of enhancing BMP-2-induced osteogenic differentiation in C2C12 myoblasts in vitro [21]. Our data demonstrates that oligosaccharides of dp10 and above were able to support this conversion, as evident by increases in osteogenic gene transcription, enhancement in ALP activity and induction of mineralization. Most notably, the animal studies confirmed the in vitro results, demonstrating that increasing chain oligosaccharide length markedly enhanced BMP-2-mediated bone formation in vivo.

[0252] We next determined the importance of specific sulfate groups within heparin/HS chains BMP-2 binding by using chemically desulfated heparin polysaccharides. A previous study has shown that rat MSCs cultured with de-2-O-sulfated heparin and BMP-2 displayed enhanced MSC proliferation and ALP activity compared to native heparin [38]. Here, N-sulfation proved critical for BMP-2 binding, whilst 6-O-sulfation was less so and 2-O-sulfation had minimal impact on binding. Re-N-acetylation of de-N-sulfated heparin partially rescued BMP-2 binding, but not to the extent of the other desulfated heparin species. Additionally, de-N-sulfated/re-N-acetylated heparin dp12s were incapable of binding BMP-2 and offered little protection from thermal stress, and was unable to enhance BMP-2 bioactivity in vitro, further emphasizing the critical role of N-sulfation in heparin; BMP-2 interactions (FIG. 12). Thus, the contribution of each sulfate group is not equal in the binding of heparin/HS chains to BMP-2, implying that a particular sequence motif underlies this phenomenon. A previous study indicated that a number of variants of desulfated heparin possessed similar net charge but differed significantly in their ability to protect BMP-2 from thermal stress [37]. These data again suggest that sequence and positioning of sulfate groups are essential in the binding of heparin to BMP-2. This result was supported by enhancement of osteogenic gene transcription, ALP activity and mineralization in vitro and the in vivo studies where N-sulfation was crucial for enhancing new bone formation. These results correlate with previous studies showing that N- and 6-O-sulfates are more important than 2-O-sulfates for binding to BMP-7 [17] and BMP-2 [37, 38]. Interestingly, 2-N, 6-O-sulfated chitosan also displayed and ability to enhance BMP-2 biological activity in vitro and in vivo, further indicating the importance of charge placement and density on polysaccharide: BMP-2 interactions [51]. In contrast, the interaction of HS with FGF-1 and FGF-2 require 2-O sulfate groups [31, 46]; although the 6-O sulfate group is less important in binding FGF-2, this substitution plays a critical role in forming the FGF-2-FGF receptor complex, a step essential for FGF-2-mediated signaling [47, 48].

[0253] Interestingly, out of all treatment groups we observed the least in vivo bone formation when BMP-2 was complexed with native heparin. This result was unexpected as complexes of BMP-2 and heparin leads to the greatest enhancement of in vitro osteogenesis. Additionally, a previous study by Zhao and colleagues (2006) observed a significant increase in bone formation using identical doses of BMP-2 and heparin, albeit using a different ectopic model [22]. Despite these differences, the observations are comparable to those made in a previous study by our own group using a similar ectopic model with identical doses of BMP-2 and heparin [32]. As eluded to in this previous study, the long-term effects of heparin could differ substantially from the effects seen over shorter periods. Furthermore, a study by Jiao and colleagues (2007) indicated that heparin can have an increasingly inhibitory effect on BMP-2 bioactivity [52]. As previously mentioned, in vivo experiments performed in the study by Ratanavaraporn and Tabata (2012) suggested de-2-O-sulfated heparin enhanced BMP-2-mediated bone formation over native heparin [38]. Moreover, the heparin oligosaccharides and selectively desulfated heparins will possess a more uniform size (in the case of the oligosaccharides) and sulfation pattern (in the case of the desulfated heparins) than native heparin. This increase in homogeneity could result in less off-target or inhibitory effects within the ectopic site. Finally, the heparin oligosaccharides are a lower molecular weight (˜2400, 3000 and 3550 Da for dp8, dp10 and dp12 respectively) than native heparin (˜15000 Da), decreasing the molar ratio between heparin dp: BMP-2 in the ectopic site and potentially resulting in an increased number of oligosaccharide: BMP-2 interactions, thus enhancing BMP-2-mediated bone formation. This may also explain why we observe a significant increase in ALP activity in C2C12 cells treated with BMP-2+dp12 versus BMP-2+heparin.

[0254] With the knowledge that heparin decasaccharides and de-2-O-sulfated heparin can enhance BMP-2-mediated in vivo bone formation, the rational design of osteoinductive biomaterials may be tuned and enhanced. Indeed, previous studies have noted that de-2-O-sulfation of heparin greatly diminishes the molecules anticoagulant properties [53], which could subsequently lead to fewer off-target effects. Zieris and co-workers (2014) developed a novel starPEG/peptide/heparin hydrogel, using desulfated heparin to sequester growth factors of interest into the biomaterial to enhance cell differentiation [54]. With knowledge of minimum oligosaccharide lengths required for binding of various growth factors and mitogens, such biomaterials could be further tuned to enhance specific interactions between proteins and scaffold, reducing unwanted side effects [55].

[0255] Although the details of the mechanism of action of the heparin fragments remain to be elaborated, it has been established that heparin acts to prolong BMP-2-induced cell signaling [22] as evidenced by the phosphorylation of Smad 1/5/9. Here we demonstrated that decasaccharides and N-sulfate groups were necessary to potentiate these effects of BMP-2 in C2C12 cells. Thus, we can conclude that BMP-2 preferences the binding to N-sulfated heparin/HS domains of dp10 or greater over other GAG subtypes. Such confirmatory information is an important step in the rational design and chemical synthesis of HS-based drugs aimed at improving bone tissue repair.

Example 4: Depolymerisation, Sizing and Compositional Analysis of HS-3 and Fragments

[0256] 4.1. Rationale

[0257] Data gathered in the heparin oligosaccharide/BMP-2 study (Examples 1-3) defined a minimal structural requirement for the effective stabilization and potentiation of BMP-2's osteoinductive properties in vitro and in vivo: [0258] At least a decamer (dp10: five disaccharides) [0259] NS >6OS >2OS—N-sulfation proved critical for BMP-2 binding, whilst 6-O-sulfation was less so and 2-O-sulfation had minimal impact on binding [0260] We therefore hypothesised that HS3 contained a BMP-2 binding region of a certain size and sulphation [0261] Due to the fundamental differences in the structure of heparin and HS, we also hypothesised that this will be structurally distinct from a heparin oligosaccharide of equivalent length. [0262] Therefore, we aimed to depolymerise HS3 into pools of oligosaccharides of various size and sulphation in a hope of determining a number of potential structures which may constitute the BMP-2 binding site within HS3. [0263] Heparinase III was used for depolymerisation. Heparinase III cleaves glycosidic linkages between GlcNAc/GlcNS and GlcA residues therefore making it ideal for excising out the highly sulphated domains of HS3.

[0264] 4.2. Depolymerisation and Sizing

[0265] Summary

[0266] HS3 was enzymatically cleaved in transition regions (N-acetylated/N-sulfated domains) to liberate the highly charged and active N-sulfated domains. 50 mIU of heparinase III was incubated with 11 mg of HS3 for 24 h, followed by a second 50 mIU addition and 24 h incubation. Digested material was then passed through a 5 kDa molecular weight cut off (MWCO) filter, and the filtrate passed through a 3 kDa MWCO filer. The filtrate and retentate of each filter was then passed over a sephadex G25 column, and material eluting in the column void region (large material) was pooled. Material larger than 5 kDa was then further fractionated by passing through a 10 kDa MWCO filter. Fractions were weighed and re-suspended at 10 mg/mL and stored at −20° C. prior to use.

[0267] Depolymerisation Procedure

[0268] 9 mg HS3 (batch 010), 6 mg HSpm (lot HO-10697) was reconstituted at 10 mg/ml in LC/MS water, and total volume brought up to 900 μL. Then 100 μL 10× heparinise buffer was added. Final salt concentration was 50 mM sodium acetate, 1 mM calcium acetate, pH 7

[0269] 25 mIU heparinise III was then added to each sample and samples were incubated at 37° C. for 24 h. A second addition of 25 mIU heparinise III was then added to each sample and samples were incubated for further 24 h at 37° C. Digestion was terminated by heating samples to 100° C. for 5 minutes before cooling on ice. Samples were frozen and lyophilised to dryness

[0270] Initial Sizing Step Procedure

[0271] Digested HS3 and HSpm were added to pre-washed 5000 Da MWCO Amicon ultra centrifugal filters (4 mL volume) and filtered by centrifuging for 30 minutes at 4000 g. Retentate was kept, filtrate was added to pre-washed 3000 Da MWCO Amicon ultra centrifugal filters (15 mL volume). Samples were filtered by centrifuging for 30 minutes at 4000 g.

[0272] Filtrate and retentate were pooled individually into groups: <3 kDa, >3k-5 Da, and >5 kDa

[0273] Desalting and Crude Second Sizing

[0274] Pooled oligosaccharides were desalted and crudely sized using a HiPrep 26/10 desalting column. Superdrex peptide 10/300 gl analytical columns were not used; trial runs resulted in minimal recovery of material, therefore different method was pursued.

[0275] Samples were loaded in 1 mL total volume followed by 1 mL water. In most cases, a clear peak was observed at the void (FIG. 13), indicating the presence of larger oligosaccharides; there were pooled and further referred to as “large”. A broad peak followed, this was pooled as small. In the case of sub-3 kDa material, no sharp peak was observed; instead a much broader peak appeared and crossed into the eluting salt peak. This is consistent with disaccharides. Peaks were pooled, lyophilised and weighed prior to reconstitution in water at 10 mg/mL.

[0276] Additional sizing—10 kDa Spin Filter

[0277] >5 kDa large HS3 and HSpm were added to pre-washed 10000 Da MWCO Amicon ultra centrifugal filters (0.5 mL volume). Samples were filtered by centrifuging for 30 minutes at 4000 g. Retentate and filtrate were frozen at −80° C. and lyophilised to dryness.

[0278] Weights of Sized HS3

[0279] HS3 >5-10 kDa—1.35 mg

[0280] HS3 >10 kDa—0.64 mg

[0281] Samples were reconstituted at 10 mg/mL in deionised water and stored at −80° C.

[0282] 4.3. Compositional Analysis of Sized HS3 Fragments

[0283] 50 μg of each HS3 fragment was digested with 1 mIU of heparinase I, II and III for 24 h at 37° C., followed by an additional 1 mIU of each enzyme and a further 24 h incubation. Digests were terminated by heating to 100° C. for 5 minutes, after which samples were frozen and lyophilised to dryness. Samples were re-suspended in 20 μL 0.1 M 2-aminoacrydone in 85% DMSO/15% acetic acid and incubated for 20 min at room temperature, protected from light. Samples were then reduced overnight with 20 μL 1M sodium cyanoborohydride. After reduction, samples were centrifuged at 13,000 rpm for 10 minutes and the supernatant transferred to a fresh tube. The supernatant was diluted to 400 μL with HPLC-grade water and passed through a 0.22 μm syringe-driven filter. Samples were analysed using a Dionex ICS-3000 high performance liquid chromatography system and resolved using an Agilent Zorbax Eclipse XDB-C18 reverse phase chromatography column. Samples were applied to the column under 95% buffer A (5% buffer B (Acetonitrile) for 1 min, before elution with a gradient of 5%-12% B over 29 min. The column was regenerated with 100% B for 5 min and re-equilibrated with 5% B for 5 min. Samples were detected with an RF2000 fluorescence emission detector (excitation wavelength—425 nm; emission wavelength—520 nm). Disaccharides were identified based on the elution points of known disaccharide standards and peak area corrected using pre-determined correction factors based on variable labelling efficiency between different disaccharide species. Data was normalised as percentage composition and represents three HPLC analysis of an individual digest per sample.

Example 5: HS3 Fragments—Experimental Data

[0284] 5.1. BMP2 Bioactivity Testing

[0285] C2C12 cells were seeded at 20,000 cells/cm2 overnight then treated the following day with the sized heparin fragments, sized HS3 fragments, full length HS3 or full length heparin at 5 μg/mL with 100 ng/mL BMP2 for 72 h. Total protein was extracted, quantified and ALP activity measured and represented as relative ALP activity versus BMP2 alone.

[0286] 5.2. Enhancement of BMP2-Mediated ALP Activity

[0287] The data indicates that increasing chain length results in increased ALP activity for both heparin and HS3 oligosaccharides. Unlike heparin fragments, which result in optimal enhancement of BMP2 activity at dp10 and maximal at dp12, HS3 fragments are of at least dp18 and above in length and optimally above dp36 (FIG. 14). This indicates that either the active domains of HS3 are markedly larger, or HS3 requires more than one active domain per chain to enhance BMP2 activity. These data reveal important differences between the two molecules, and suggest that the data generated in the manuscript will not significantly impact on work to elucidate the binding mechanism of HS3 to BMP2.

[0288] 5.3. Compositional Analysis of HS3 Fragments

[0289] Compositional analysis reveals an obvious trend between length and overall sulphation. The smallest fragments (below a dp12) contain the lowest degree of sulphation (FIG. 15), additionally they possess a greater amount of 2-O-sulphation than 6-O-sulphation, again correlating with data from the manuscript suggesting 6-O-sulphation is more important than 2-O-sulphation in the binding of HS to BMP2. Fragments of 18-36 saccharides display an ability to enhance BMP2-mediated bioactivity, these also contain a higher abundance of sulphation and are compositionally similar to the parental material (HS3 full length, FIGS. 15 and 16). The greatest enhancement of BMP2-mediated bioactivity is induced by fragments above 36 saccharides in length; these are also the most abundantly sulphated species, composed of ˜25% trisulphated disaccharides and the highest proportion of N-sulphated, 6-O-sulphated disaccharides (FIGS. 15-17). They also possess the lowest percentage of unmodified disaccharides (table 1, 17.4%). These data suggest that N and 6-O-sulphation are important for the enhancement of BMP2-mediated bioactivity, which correlates with our hypothesis that 2-O-sulphation is the least important modification for enhancing BMP2-mediated bioactivity.

[0290] 5.4. Compositional Comparisons Between Heparin Dp12 and HS3 >Dp36

[0291] FIGS. 18, 19 and 20 compare the overall composition of a heparin dp12 and HS3 >dp36, which are the most biologically active fragments derived from heparin and HS3, respectively. Structurally, each is distinctly different; the heparin dp12 is predominantly composed of trisulphated residues (Table 2, 79%), whereas the HS3 >dp36 contains more mono and disulphated residues with 6-O-sulphation than heparin (14.48% 6-O and 12.97% N-, 6-O vs 2.88% 6-O and 6.03% N-, 6-O, respectively). These data on bioactivity and composition reveal important differences between the two molecules (HS3 >dp36 and heparin dp12), and suggest that the data generated in the manuscript will not significantly impact on work to elucidate the binding mechanism of HS3 to BMP2.

REFERENCES

[0292] [1] B. L. Hogan, Bone morphogenetic proteins: multifunctional regulators of vertebrate development, Genes Dev 10(13) (1996) 1580-94. [0293] [2] A. H. Reddi, Bone and cartilage differentiation, Curr Opin Genet Dev 4(5) (1994) 737-44. [0294] [3] E. H. Groeneveld, E. H. Burger. Bone morphogenetic proteins in human bone regeneration, Eur J Endocrinol 142(1) (2000) 9-21. [0295] [4] T. J. Kleeman, U. M. Ahn, A. Talbot-Kleeman, Laparoscopic anterior lumbar interbody fusion with rhBMP-2: a prospective study of clinical and radiographic outcomes, Spine (Phila Pa 1976) 26(24) (2001) 2751-6. [0296] [5] J. K. Burkus, E. E. Transfeldt, S. H. Kitchel, R. G. Watkins, R. A. Balderston, Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2, Spine (Phila Pa 1976) 27(21) (2002) 2396-408. [0297] [6] B. McKay, H. S. Sandhu, Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications, Spine (Phila Pa 1976) 27(16 Suppl 1) (2002) S66-85. [0298] [7] A. R. Poynton, J. M. Lane, Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine (Phila Pa 1976) 27(16 Suppl 1) (2002) S40-8. [0299] [8] K. Miyazono, K. Kusanagi, H. Inoue. Divergence and convergence of TGF-beta/BMP signaling, J Cell Physiol 187(3) (2001) 265-76. [0300] [9] A. Nohe, S. Hassel, M. Ehrlich, F. Neubauer, W. Sebald, Y. I. Henis, P. Knaus, The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways, J Biol Chem 277(7) (2002) 5330-8. [0301] [10] H. Aoki, M. Fujii, T. Imamura, K. Yagi, K. Takehara. M. Kato, K. Miyazono, Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction, J Cell Sci 114(Pt 8) (2001) 1483-9. [0302] [11]J. Massague, Y. G. Chen, Controlling TGF-beta signaling, Genes Dev 14(6) (2000) 627-44. [0303] [12] L. Attisano, J. L. Wrana. Smads as transcriptional co-modulators, Curr Opin Cell Biol 12(2) (2000) 235-43. [0304] [13] A. H. Reddi, Bone morphogenetic proteins: from basic science to clinical applications, J Bone Joint Surg Am 83-A Suppl 1(Pt 1) (2001) S1-6. [0305] [14] T. Katagiri, N. Takahashi, Regulatory mechanisms of osteoblast and osteoclast differentiation, Oral Dis 8(3) (2002) 147-59. [0306] [15] E. Forsberg, L. Kjellen, Heparan sulfate: lessons from knockout mice, J Clin Invest 108(2) (2001) 175-80. [0307] [16] S. Grisaru, D. Cano-Gauci, J. Tee, J. Filmus, N. D. Rosenblum, Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis, Dev Biol 231(1) (2001) 31-46. [0308] [17] A. Irie, H. Habuchi, K. Kimata, Y. Sanai, Heparan sulfate is required for bone morphogenetic protein-7 signaling, Biochem Biophys Res Commun 308(4) (2003) 858-65. [0309] [18] S. Paine-Saunders, B. L. Viviano, A. N. Economides, S. Saunders, Heparan sulfate proteoglycans retain Noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients, J Biol Chem 277(3) (2002) 2089-96. [0310] [19] S. Paine-Saunders, B. L. Viviano, J. Zupicich, W. C. Skarnes, S. Saunders, glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development, Dev Biol 225(1) (2000) 179-87. [0311] [20] T. Takada, T. Katagiri, M. Ifuku, N. Morimura, M. Kobayashi, K. Hasegawa, A. Ogamo. R. Kamijo, Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins, J Biol Chem 278(44) (2003) 43229-35. [0312] [21]T. Katagiri, A. Yamaguchi, M. Komaki, E. Abe, N. Takahashi, T. Ikeda, V. Rosen, J. M. Wozney, A. Fujisawa-Sehara, T. Suda, Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage, J Cell Biol 127(6 Pt 1) (1994) 1755-66. [0313] [22] B. Zhao, T. Katagiri, H. Toyoda, T. Takada, T. Yanai, T. Fukuda, U. I. Chung, T. Koike, K. Takaoka, R. Kamijo, Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2, J Biol Chem 281(32) (2006) 23246-53. [0314] [23] D. A. Pye, J. T. Gallagher, Monomer complexes of basic fibroblast growth factor and heparan sulfate oligosaccharides are the minimal functional unit for cell activation, J Biol Chem 274(19) (1999) 13456-61. [0315] [24] M. Lyon, G. Rushton. J. A. Askari, M. J. Humphries, J. T. Gallagher, Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin, J Biol Chem 275(7) (2000) 4599-606. [0316] [25] O. Ostrovsky, B. Berman, J. Gallagher, B. Mulloy, D. G. Fernig, M. Delehedde, D. Ron, Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes, J Biol Chem 277(4) (2002) 2444-53. [0317] [26] I. Capila, R. J. Linhardt, Heparin-protein interactions, Angew Chem Int Ed Engl 41(3) (2002) 391-412. [0318] [27] D. Loganathan, H. M. Wang, L. M. Mallis, R. J. Linhardt, Structural variation in the antithrombin Ill binding site region and its occurrence in heparin from different sources, Biochemistry 29(18) (1990) 4362-8. [0319] [28] J. Choay, M. Petitou, J. C. Lormeau, P. Sinay, B. Casu, G. Gatti, Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity, Biochem Biophys Res Commun 116(2) (1983) 492-9. [0320] [29] S. T. Olson. I. Bjork, R. Sheffer, P. A. Craig, J. D. Shore, J. Choay, Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267(18) (1992) 12528-38. [0321] [30] U. Lindahl, G. Backstrom, M. Hook, L. Thunberg. L. A. Fransson, A. Linker, Structure of the antithrombin-binding site in heparin, Proc Natl Acad Sci USA 76(7) (1979) 3198-202. [0322] [31] J. E. Turnbull, D. G. Fernig. Y. Ke, M. C. Wilkinson, J. T. Gallagher, Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate, J Biol Chem 267(15) (1992) 10337-41. [0323] [32] D. S. Bramono, S. Murali, B. Rai, L. Ling, W. T. Poh, Z. X. Lim, G. S. Stein, V. Nurcombe, A. J. van Wijnen, S. M. Cool, Bone marrow-derived heparan sulfate potentiates the osteogenic activity of bone morphogenetic protein-2 (BMP-2), Bone 50(4) (2012) 954-64. [0324] [33] R. A. A. Smith, R. J. E. Chua, S. M. Carnachan, C. L. L. Tan, I. M. Sims, S. F. R. Hinkley, V. Nurcombe, S. M. Cool, Retention of the Structure and Function of Heparan Sulfate Biomaterials After Gamma Irradiation, Tissue Eng Part A 24(9-10) (2018) 729-739. [0325] [34] S. Murali, B. Rai, C. Dombrowski, J. L. Lee, Z. X. Lim, D. S. Bramono, L. Ling, T. Bell, S. Hinkley, S. S. Nathan, J. H. Hui, H. K. Wong, V. Nurcombe, S. M. Cool, Affinity-selected heparan sulfate for bone repair, Biomaterials 34(22) (2013) 5594-605. [0326] [35] B. Rai, J. L. Lin, Z. X. Lim, R. E. Guldberg, D. W. Hutmacher, S. M. Cool, Differences between in vitro viability and differentiation and in vivo bone-forming efficacy of human mesenchymal stem cells cultured on PCL-TCP scaffolds, Biomaterials 31(31) (2010) 7960-70. [0327] [36] J. Lee, S. Wee, J. Gunaratne, R. J. Chua, R. A. Smith, L. Ling, D. G. Fernig, K. Swaminathan, V. Nurcombe, S. M. Cool, Structural determinants of heparin-transforming growth factor-beta1 interactions and their effects on signaling, Glycobiology 25(12) (2015) 1491-504. [0328] [37] S. F. Seto. T. Miller, J. S. Temenoff, Effect of selective heparin desulfation on preservation of bone morphogenetic protein-2 bioactivity after thermal stress, Bioconjug Chem 26(2) (2015) 286-93. [0329] [38] J. Ratanavaraporn, Y. Tabata, Enhanced osteogenic activity of bone morphogenetic protein-2 by 2-O-desulfated heparin, Acta biomaterialia 8(1) (2012) 173-82. [0330] [39] P. C. Tyler, S. E. Guimond, J. E. Turnbull, O. V. Zubkova, Single-entity heparan sulfate glycomimetic clusters for therapeutic applications, Angew Chem Int Ed Engl 54(9) (2015) 2718-23. [0331] [40] R. Schworer, O. V. Zubkova, J. E. Turnbull, P. C. Tyler, Synthesis of a targeted library of heparan sulfate hexa- to dodecasaccharides as inhibitors of beta-secretase: potential therapeutics for Alzheimer's disease. Chemistry 19(21) (2013) 6817-23. [0332] [41] S. S. Deepa, Y. Umehara, S. Higashiyama, N. Itoh, K. Sugahara, Specific molecular interactions of oversulfated chondroitin sulfate E with various heparin-binding growth factors. Implications as a physiological binding partner in the brain and other tissues, J Biol Chem 277(46) (2002) 43707-16. [0333] [42] U. Lindahl, G. Backstrom, L. Thunberg, I. G. Leder, Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin, Biochemistry 77(11) (1980) 6551-6555. [0334] [43] U. Lindahl, L. Thunberg, G. Backstrom, J. Riesenfeld, K. Nordling, I. Bjork, Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem 259(20) (1984) 12368-76. [0335] [44] L. Thunberg, G. Backstrom, U. Lindahl, Further characterization of the antithrombin-binding sequence in heparin, Carbohydr Res 100 (1982) 393-410. [0336] [45] C. J. Robinson, N. J. Harmer, S. J. Goodger, T. L. Blundell, J. T Gallagher, Cooperative dimerilation of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes, J Biol Chem 280(51) (2005) 42274-82. [0337] [46] M. Guerrini, T. Agulles, A. Bisio, M. Hricovini. L. Lay, A. Naggi, L. Poletti, L. Sturiale, G. Torri, B. Casu, Minimal heparin/heparan sulfate sequences for binding to fibroblast growth factor-1, Biochem Biophys Res Commun 292(1) (2002) 222-30. [0338] [47] D. A. Pye, R. R. Vives, P. Hyde, J. T. Gallagher, Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2, Glycobiology 10(11) (2000) 1183-92. [0339] [48] S. Guimond, M. Maccarana, B. B. Olwin, U. Lindahl, A. C. Rapraeger, Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4, J Biol Chem 268(32) (1993) 23906-14. [0340] [49] K. A. Radek, K. R. Taylor, R. L. Gallo, FGF-10 and specific structural elements of dermatan sulfate size and sulfation promote maximal keratinocyte migration and cellular proliferation, Wound Repair Regen 17(1) (2009) 118-26. [0341] [50] K. R. Taylor, J. A. Rudisill, R. L. Gallo, Structural and sequence motifs in dermatan sulfate for promoting fibroblast growth factor-2 (FGF-2) and FGF-7 activity, J Biol Chem 280(7) (2005) 5300-6. [0342] [51] H. Zhou, J. Qian, J. Wang, W. Yao, C. Liu, J. Chen, X. Cao, Enhanced bioactivity of bone morphogenetic protein-2 with low dose of 2-N, 6-O-sulfated chitosan in vitro and in vivo, Biomaterials 30(9) (2009) 1715-24. [0343] [52] X. Jiao, P. C. Billings, M. P. O'Connell. F. S. Kaplan, E. M. Shore, D. L. Glaser, Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells, J Biol Chem 282(2) (2007) 1080-6. [0344] [53] U. Freudenberg, A. Zieris, K. Chwalek, M. V. Tsurkan, M. F. Maitz, P. Atallah, K. R. Levental, S. A. Erring, C. Werner, Heparin desulfation modulates VEGF release and angiogenesis in diabetic wounds, J Control Release 220(Pt A) (2015) 79-88. [0345] [54] A. Zieris, R. Dockhorn, A. Rohrich, R. Zimmermann, M. Muller, P. B. Welzel, M. V. Tsurkan, J. U. Sommer, U. Freudenberg, C. Werner, Biohybrid networks of selectively desulfated glycosaminoglycans for tunable growth factor delivery, Biomacromolecules 15(12) (2014) 4439-46. [0346] [55] U. Freudenberg, Y. Liang, K. L. Kiick, C. Werner, Glycosaminoglycan-Based Biohybrid Hydrogels: A Sweet and Smart Choice for Multifunctional Biomaterials, Adv Mater 28(40) (2016) 8861-8891. [0347] [56] D. Xu, J. D. Esko, Demystifying Heparan Sulfate-Protein Interactions, Annual review of biochemistry 83 (2014) 129-157. [0348] [57] A. Ori, M. C. Wilkinson, D. G. Fernig, A systems biology approach for the investigation of the heparin/heparan sulfate interactome, J Biol Chem 286(22) (2011) 19892-904. [0349] [58] B. I. Ayerst, R. A. Smith, V. Nurcombe, A. J. Day, C. L. Merry, S. M. Cool, Growth Differentiation Factor 5-Mediated Enhancement of Chondrocyte Phenotype Is Inhibited by Heparin: Implications for the Use of Heparin in the Clinic and in Tissue Engineering Applications, Tissue Eng Part A 23(7-8) (2017) 275-292. [0350] [59] A. Walker, J. E. Turnbull, J. T. Gallagher, Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J Biol Chem 269(2) (1994) 931-5. [0351] [60] J. Kreuger, K. Prydz, R. F. Pettersson, U. Lindahl, M. Salmivirta, Characterization of fibroblast growth factor 1 binding heparan sulfate domain, Glycobiology 9(7) (1999) 723-729. [0352] [61] J. Kreuger, M. Salmivirta, L. Sturiale, G. Gimenez-Gallego, U. Lindahl, Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2, The Journal of Biological Chemistry 276(33) (2001) 30744-52. [0353] [62] D. Spillmann, D. Witt, U. Lindahl, Defining the Interleukin-8-binding Domain of Heparan Sulfate, The Journal of Biological Chemistry 273(25) (1998) 15487-15493. [0354] [63] N. S. Gandhi, R. L. Mancera, Prediction of heparin binding sites in bone morphogenetic proteins (BMPs), Biochim Biophys Acta 1824(12) (2012) 1374-81. [0355] [64] B. Rai, A. Chatterjea, Z. X. Lim, T. C. Tan, A. A. Sawyer, Y. Z. Hosaka, S. Murali, J. J. Lee, S. A. Fenwick, J. H. Hui, V. Nurcombe, S. M. Cool, Repair of segmental ulna defects using a beta-TCP implant in combination with a heparan sulfate glycosaminoglycan variant, Acta biomaterialia 28 (2015) 193-204. [0356] [65] K. A. Uniewicz, A. Ori, R. Xu, Y. Ahmed, M. C. Wilkinson, D. G. Fernig. E. A. Yates, Differential Scanning Fluorimetry Measurement of Protein Stability Changes upon Binding to Glycosaminoglycans: A Screening Test for Binding Specificity, Anal Chem 82(9) (2010) 3796-3802. [0357] [66] H. S. Yang, W. G. La, S. H. Bhang, J. Y. Jeon, J. H. Lee, B. S. Kim, Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2, Tissue Eng Part A 16(4) (2010) 1225-33. [0358] [67] Z. A. Ralis. and Watkins, K., Modified tetrachrome method for osteoid and defectively mineralized bone in paraffin sections, Biotech and Histochem 67(6) (1992) 339-345.